3
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Drug Design, Development and Therapy (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the design and development of drugs, as well as the clinical outcomes, patient safety, and programs targeted at the effective and safe use of medicines. Sign up for email alerts here.

      88,007 Monthly downloads/views I 4.319 Impact Factor I 6.6 CiteScore I 1.12 Source Normalized Impact per Paper (SNIP) I 0.784 Scimago Journal & Country Rank (SJR)

       

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of Remimazolam Tosilate on Respiratory Depression in Elderly Patients Undergoing Gastroscopy: A Multicentered, Prospective, and Randomized Study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Remimazolam tosilate (RT) is a new type of γ-aminobutyric acid subtype A (GABA A) receptor agonist, having the possibility to be an ideal sedative drug for procedural sedation. At present, there are few studies on the effect of RT on respiratory depression in elderly patients. We aimed to evaluate the effect of RT on respiratory depression in elderly patients undergoing gastroscopy.

          Methods

          This prospective, randomized, single-blinded trial recruited patients from eight centers in China between May 2022 and July 2022. A total of 346 elderly patients undergoing gastroscopy were randomly divided into RT group (0.2 mg/kg) or propofol group (1.5 mg/kg), respectively. The primary outcome was the incidence of respiratory depression. Secondary outcomes include the incidence of sedative-related adverse events, the success rate of sedation, time to fully alert, time to loss of consciousness (LOC), time to ready for discharge, as well as the the patients, endoscopists and anethetists’ satisfaction.

          Results

          The incidence of respiratory depression was significantly reduced in the RT group compared with the propofol group (9.8% vs 17.9%, P=0.042). The time of LOC and fully alert in the RT group were longer than that in the propofol group (P < 0.05). The incidences of hypotention (50.9% vs 32.4%, P=0.001) and hypotension requiring treatment (5.8% vs 1.7%, P=0.031) were significantly higher in the propofol group than that in the RT group. The incidence and severity of injection pain were more frequently recorded in the propofol group than that in the RT group (40.5% vs 12.1%, P<0.05). There were no statistically significant differences between the two groups in terms of sedation success rates, time to ready for discharge, endoscopists and anethetists’ satisfaction and other sedative-related adverse events.

          Conclusion

          RT may be a suitable alternative sedative agent for elderly patients undergoing gastroscopy due to its safety profile.

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam.

          The Observer's Assessment of Alertness/Sedation (OAA/S) Scale was developed to measure the level of alertness in subjects who are sedated. This scale was tested in 18 subjects in a three-period crossover study to assess its reliability and its criterion, behavioral, and construct validity. After receiving either placebo or a titrated dose of midazolam to produce light or heavy sedation, each subject was administered two sedation scales (OAA/S Scale and a Visual Analogue Scale) and two performances tests (Digit Symbol Substitution Test and Serial Sevens Subtraction). Two raters individually evaluated the subject's level of alertness on each of the two sedation scales. The results obtained on the OAA/S Scale were reliable and valid as measured by high correlations between the two raters and high correlations between the OAA/S Scale and two of the three standard tests used in this study. The OAA/S Scale was sensitive to the level of midazolam administered; all pairwise comparisons were significant (p less than 0.05) for all three treatment levels at both test periods.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.

            A new benzodiazepine, remimazolam, metabolized by tissue esterases to an inactive compound, CNS 7054, has been developed to permit a fast onset, a short and more predictable duration of sedative action, and a more rapid recovery profile than with currently available benzodiazepines. We report on the safety and efficacy of the first human study. A phase I, single-center, double-blind, placebo- and active-controlled, randomized, single-dose escalation study was conducted. Up to 10 cohorts of healthy subjects were scheduled to receive a single 1-minute IV infusion of remimazolam, midazolam, or placebo. In the 10 possible cohorts, remimazolam doses were from 0.01 to 0.35 mg/kg. In cohorts 1 to 3, 6 subjects received remimazolam and 1 placebo. From cohort 4 onward, an additional 3 subjects in each cohort received midazolam (0.075 mg/kg). Safety, pharmacokinetics, and pharmacodynamics were measured. A stop criterion of loss of consciousness for >5 minutes in >50% of subjects was predefined. The stop criterion was reached in cohort 9 (0.30 mg/kg remimazolam) so that 81 subjects were enrolled. Remimazolam was well tolerated in all dose cohorts, and no serious adverse events (AEs) were reported. Three AEs of mild (Spo(2) 85%-88%) hemoglobin desaturation (2 in the remimazolam groups and 1 in the midazolam group) resolved spontaneously, and 1 AE of moderate hemoglobin desaturation (Spo(2) 75%) resolved with a chin lift in the highest remimazolam dose group. No supplemental oxygen or manual ventilation was required. Vital signs remained stable throughout, although there was an increase in heart rate 2 minutes postdose for both remimazolam and midazolam. There were no reports of hypo- or hypertension. The pharmacokinetic behavior of remimazolam was linear and its systemic clearance approximately 3 times that of midazolam. Clearance was essentially independent of body weight. A rapid onset and dose-dependent sedation was observed after administration of remimazolam at 0.05 mg/kg and higher. Remimazolam (0.075 to 0.20 mg/kg) induced peak sedation levels similar to or higher than those achieved with midazolam (0.075 mg/kg). Median recovery times after approximately equieffective doses of remimazolam (0.10 and 0.15 mg/kg) and midazolam (0.075 mg/kg) were 10 and 40 minutes, respectively. Remimazolam provided sedation with rapid onset and offset, and was well tolerated. There was no supplemental oxygen or ventilation required. On the basis of these data, further studies on the potential utility of remimazolam for sedation/anesthesia are warranted.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non‐inferiority, phase III trial

              Remimazolam tosilate (RT) is a new short-acting GABA(A) receptor agonist, having potential to be an effective option for procedural sedation. Here, we aimed to compare the efficacy and safety of RT with propofol in patients undergoing upper gastrointestinal endoscopy.
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                dddt
                Drug Design, Development and Therapy
                Dove
                1177-8881
                05 December 2022
                2022
                : 16
                : 4151-4159
                Affiliations
                [1 ]Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University , Guiyang, People’s Republic of China
                [2 ]College of Anesthesiology, Guizhou Medical University , Guiyang, People’s Republic of China
                [3 ]Department of Anesthesiology, The Second Affiliated Hospital of Zunyi Medical University , Zunyi, People’s Republic of China
                [4 ]Department of Anesthesiology, The First People’ s Hospital of Bijie City , Bijie, People’s Republic of China
                [5 ]Department of Anesthesiology, Dali Bai Autonomous Prefecture People’s Hospital , Dali, People’s Republic of China
                [6 ]Department of Anesthesiology, The People’s Hospital of Qiannan , Qiannan, People’s Republic of China
                [7 ]Department of Anesthesiology, The First People’s Hospital of Guiyang , Guiyang, People’s Republic of China
                [8 ]Department of Anesthesiology, The Second People’s Hospital of Guiyang , Guiyang, People’s Republic of China
                [9 ]Department of Anesthesiology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine , Guiyang, People’s Republic of China
                Author notes
                Correspondence: Xiaohua Zou; Songjiang Tan, Fax +86-851-86771013, Email zouxiaohuazxh@163.com; 214459348@qq.com
                [*]

                These authors contributed equally to this work

                Author information
                https://orcid.org/http://orcid.org/0000-0003-1126-5381
                Article
                391147
                10.2147/DDDT.S391147
                9733689
                36506792
                2cce8f21-4cc7-4ab6-940c-854eab800ffa
                © 2022 Hu et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 29 September 2022
                : 26 November 2022
                Page count
                Figures: 1, Tables: 5, References: 28, Pages: 9
                Funding
                Funded by: Beijing Hongyi Medical Development Foundation;
                Funded by: Yunyan District Science and Technology department;
                Funded by: Natural Science Foundation of China, open-funder-registry 10.13039/501100001809;
                Funded by: Science and Technology Fund of Guizhou Provincial Health Department;
                Funded by: Guizhou Provincial Natural Science Foundation;
                Funded by: Natural Science Foundation of China, open-funder-registry 10.13039/501100001809;
                Funded by: Guiyang Science and Technology department;
                Funded by: Health and Family Planning Commission of Guizhou Province;
                Funded by: Guizhou Provincial Education Department;
                This work was supported in part by grants from the Beijing Hongyi Medical Development Foundation (HY20210037-A-07), the Fund of Yunyan District Science and Technology department (yunkehezi[2021]10), Natural Science Foundation of China (No. 82160951, 82162024), the Science and Technology Fund of Guizhou Provincial Health Department (qiankehepingtairencai[2018]5779-52), the Fund of Guizhou Provincial Natural Science Foundation (qiankehejichu[2020]1Y298), the Cultivate project 2021 for National Natural Science Foundation of China, Affiliated Hospital of Guizhou Medical University (gyfynsfc-2021-35), the Fund of Guiyang Science and Technology department ([2019]9-1-24), the Health and Family Planning Commission of Guizhou Province (gzwkj2021-273), the Fund of Guizhou Provincial Education Department (qianjiaoheKYzi[2021]182).
                Categories
                Original Research

                Pharmacology & Pharmaceutical medicine
                remimazolam tosilate,propofol,elderly patients,gastroscopy

                Comments

                Comment on this article